Stock Updates

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) – Is this large market cap stock undervalued?

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), is firmly in the large market cap category with market cap of 22012.77. To be considered a large market cap stock companies have to be valued at more than $10 billion. The current price for Vertex Pharmaceuticals Incorporated is 88.84 (with a change from open of -1.85%), this in conjunction with a target price of 110.26. Volume today has so far reached 1685863, with an average volume of about 1335.83. The GAP for this stock, is 1.56%.

The P/E ratio is *TBA, bringing the forward P/E to a value of 30.02. The current EPS for Vertex Pharmaceuticals Incorporated, is -1.13, with a EPS growth for this year coming to a value of 26.50%. Performance has been interesting with performance year to date coming to -29.40%.

Looking further into the growth statistics for Vertex Pharmaceuticals Incorporated, EPS is looking like it will grow 197.09% in the next year. Looking even further it is projected to be 53.30%. Quarter over quarter is 66.40% for EPS growth and for sales growth quarter over quarter it is 159.80%. Looking at past EPS growth statistics we see that for the past five years it has been 9.30%. Sales growth for the past five years has in fact been 48.40%.

Looking at the ownership, we see that the insider ownership is at 0.30% and institutional ownership is 97.80%. Shares outstanding is 247.78, while shares float is at a value of 246.06. Float short for Vertex Pharmaceuticals Incorporated is 2.26% and the short ratio is 4.16.

In terms of debt, long term debt/equity is 0.59, while the total debt/equity comes to 0.84. The ability to meet these debts, means that the current ratio is 2.3, and the quick ratio is 2.2. The most recent gross margin is 88.00% and their operating margin is -8.70%. The profit margin is -17.70%.

Vertex Pharmaceuticals Incorporated has seen returns on assets of -11.00%, and on investment, -28.20%. Return on equity is -28.90%. Price/Earnings to growth ratio is *TBA. Price/Sales ratio is at a value of 14.13, with Price/book ratio coming to 22.15 and Price/cash is 20.54, and finally Price/Free cash Flow is 81.53.

The simple moving averages are -7.63% and -4.14% for 20 day and 200 day simple moving average respectively. For the 52 week high and low the 52 week high is -34.05% and the 52 week low is 17.05%.

Vertex Pharmaceuticals Incorporated has a dividend yield of *TBA, with a current price of 88.84. The ability to pay this means the payout ratio is *TBA. This is in an industry, Biotechnology, with equally high dividends from other companies in this sector, which it is Healthcare. Vertex Pharmaceuticals Incorporated is based in USA.

Performance in the Biotechnology industry means that Vertex Pharmaceuticals Incorporated has seen performance for the past week of -3.25%, with performance for the month coming to -8.36%. Looking at the data for the quarter it is at a value of 4.52%, and for the half year the performance is -11.01%. Volatility for this week is 3.38% and for the month this is 3.53%.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Peter Clarke

Leave a Comment